MU, M., JF, D., J, A., BW, C., G, K., D, K., . . . LS, M. (2026). A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. Blood, 147(17), 1914. https://doi.org/10.1182/blood.2025031053
Chicago Style (17th ed.) CitationMU, Mushtaq, et al. "A Phase 1/2 Study of Donor-derived Anti-CD33 CAR T-cell Therapy (VCAR33) for Relapsed/refractory AML After Allogeneic HCT." Blood 147, no. 17 (2026): 1914. https://doi.org/10.1182/blood.2025031053.
MLA (9th ed.) CitationMU, Mushtaq, et al. "A Phase 1/2 Study of Donor-derived Anti-CD33 CAR T-cell Therapy (VCAR33) for Relapsed/refractory AML After Allogeneic HCT." Blood, vol. 147, no. 17, 2026, p. 1914, https://doi.org/10.1182/blood.2025031053.
Warning: These citations may not always be 100% accurate.
